Details for New Drug Application (NDA): 208780
✉ Email this page to a colleague
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the pirfenidone profile page.
Summary for 208780
Tradename: | ESBRIET |
Applicant: | Genentech Inc |
Ingredient: | pirfenidone |
Patents: | 16 |
Suppliers and Packaging for NDA: 208780
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ESBRIET | pirfenidone | TABLET;ORAL | 208780 | NDA | Genentech, Inc. | 50242-122 | 50242-122-06 | 1 BOTTLE, PLASTIC in 1 CARTON (50242-122-06) / 270 TABLET, COATED in 1 BOTTLE, PLASTIC |
ESBRIET | pirfenidone | TABLET;ORAL | 208780 | NDA | Genentech, Inc. | 50242-122 | 50242-122-86 | 1 BOTTLE, PLASTIC in 1 CARTON (50242-122-86) / 189 TABLET, COATED in 1 BOTTLE, PLASTIC |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 267MG | ||||
Approval Date: | Jan 11, 2017 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Sign Up | Patent Expiration: | Mar 28, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 22, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 22, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF |
Expired US Patents for NDA 208780
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | ⤷ Sign Up | ⤷ Sign Up |
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | ⤷ Sign Up | ⤷ Sign Up |
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription